[EN] FUSED HETEROCYCLIC INHIBITORS OF FACTOR XA<br/>[FR] INHIBITEURS HETEROCYCLIQUES FUSIONNES DU FACTEUR XA
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2002080853A2
公开(公告)日:2002-10-17
This invention relates generally to a novel class of fused heterocyclic compounds of the Formula (I) or Formula (II): or pharmaceutically acceptable salt forms thereof, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
Fused heterocyclic inhibitors of factor Xa
申请人:——
公开号:US20030087909A1
公开(公告)日:2003-05-08
This invention relates generally to a novel class of fused heterocyclic compounds of the Formula (I) or Formula (II):
1
or pharmaceutically acceptable salt forms thereof, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.